Ryan Fagan

Ryan Fagan joined Gryphon Investors in 2007 and is a member of the firm’s Consumer Group. Gryphon’s current team page lists him as a Deal Partner responsible for originating, executing, and managing investments, with a current focus on Better-For-You Food & Beverage and Consumer Health & Wellness.

Fagan currently has board appointments at Mechanix Wear, Metagenics, and Spindrift. Gryphon also says he supported prior investments in Dessert Holdings, Flagstone Foods, Fleet Laboratories, K&N Engineering, Matrixx Initiatives/ZICAM, and RoC Skincare.

Before Gryphon, Fagan worked as an investment banker at Merrill Lynch in the consumer and retail group. He holds a B.S. in Economics from The Wharton School at the University of Pennsylvania and a J.D. from Columbia Law School.

• Fagan’s current mandate is consumer-focused, especially Better-For-You Food & Beverage and Consumer Health & Wellness.
• Gryphon targets middle-market companies where it can form strong partnerships with founders, owners, and management teams, then use its integrated deal and operations model to accelerate growth.
• Gryphon’s stated investment criteria favor “market leaders with strong underlying demographics and robust demand drivers” and opportunities for strategic and operational enhancements rather than financial engineering.
• The firm’s private-equity strategy targets $50 million to $500 million investments in North America-headquartered businesses with EBITDA up to $80 million.
• In consumer health, Fagan has emphasized “leading brands and experienced executives” as part of Gryphon’s proactive sector work.
• On Metagenics, Fagan said Gryphon was looking for a platform with scientific credibility, quality, innovation, sourcing transparency, and exposure to proactive health and wellness.
• On Spindrift, Fagan highlighted a beloved brand, differentiated product portfolio, quality focus, and outsized growth across beverage categories as reasons Gryphon invested.